Author

K. W. Bock

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 10 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 11 Research Focus:host-pathogen & immune response· 10 Organism:non-human primate· 8 Organism:mouse· 4 Assay:proteomics· 4 Research Focus:cell type annotation· 3 Research Focus:drug response / drug discovery· 3 Research Focus:differential expression· 2

Frequent Co-Authors

B. M. Nagata· 10 shared M. Minai· 9 shared M. Gagne· 6 shared A. Cook· 5 shared A. Dodson· 5 shared K. S. Corbett· 5 shared S. Boyoglu-Barnum· 5 shared S. T. Nurmukhambetova· 5 shared

Activity by Year

2020-2023 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

10 shared papersImmunology

B. M. Nagata

Mutual co-authors in cluster

Author profile →

11 papers

Recent·Most cited

Broadly neutralizing antibody induction by non-stabilized SARS-CoV-2 Spike mRNA vaccination in nonhuman primates

R. D. Malewana, V. Stalls, A. May, X. Lu, D. R. Martinez, A. Schafer, D. Li, M. Barr, L. L. Sutherland, E. Lee, R. Parks, W. E. Beck, A. Newman, K. W. Bock, M. Minai, , K. O. Saunders

Non-stabilized SARS-CoV-2 Spike mRNA vaccination in macaques induces B cell lineages targeting conserved epitopes on Omicron variants or cross-neutralizing epitopes on Sarbecoviruses.

bioRxiv · Dec 18, 2023 · PreprintImmunology

Commercial influenza vaccines vary in both the structural arrangements of HA complexes and in induction of antibodies to cross-reactive HA epitopes

M. L. Myers, J. R. Gallagher, A. J. Kim, W. H. Payne, K. W. Bock, U. Torian, I. N. Moore, A. K. Harris

This study examines how different structural arrangements of hemagglutinin (HA) in commercial influenza vaccines correlate with the induction of cross-reactive antibodies.

bioRxiv · Sep 22, 2022 · PreprintMicrobiology

mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron

M. Gagne, J. I. Moliva, K. E. Foulds, S. F. Andrew, B. J. Flynn, A. P. Werner, D. A. Wagner, I.-T. Teng, B. C. Lin, C. Moore, N. Jean-Baptiste, R. Carroll, S. L. Foster, M. Patel, M. Ellis, , Naisan

This study compares B cell responses and protection against Omicron after boosting vaccinated macaques with mRNA-1273 or mRNA-Omicron vaccines, finding comparable immunity and protection.

bioRxiv · Feb 3, 2022 · PreprintImmunology

Breadth of SARS-CoV-2 Neutralization and Protection Induced by a Nanoparticle Vaccine

D. Li, D. R. Martinez, A. Schäfer, H. Chen, M. Barr, L. L. Sutherland, E. Lee, R. Parks, D. Mielke, W. Edwards, A. Newman, K. W. Bock, M. Minai, B. M. Nagata, M. Gagne, , B. F. Haynes

This study shows a nanoparticle vaccine induces broad neutralizing antibodies against multiple SARS-CoV-2 variants and protects non-human primates and mice from viral challenges.

bioRxiv · Jan 26, 2022Immunology

Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway

M. Gagne, K. S. Corbett, B. J. Flynn, K. E. Foulds, D. A. Wagner, S. F. Andrew, J.-P. M. Todd, C. C. Honeycutt, L. McCormick, S. T. Nurmukhambetova, M. E. Davis-Gardner, L. Pessaint, K. W. Bock, B. M. Nagata, M. Minai, , B. S. Graham

This study shows that mRNA-1273 vaccine protection against SARS-CoV-2 Delta in nonhuman primates persists for one year but is delayed and relies on anamnestic antibody responses in the lower airway.

bioRxiv · Oct 23, 2021 · PreprintImmunology

Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates

K. S. Corbett, M. Gagne, D. Wagner, S. O'Connell, S. R. Narpala, D. R. Flebbe, S. F. Andrew, R. L. Davis, B. Flynn, T. S. Johnston, C. Stringham, L. Lai, D. Valentin, A. Van Ry, Z. Flinchbaugh, , A Pekosz

mRNA-1273 boosted nonhuman primates show increased neutralizing antibody responses and protection against SARS-CoV-2 beta variant infection.

bioRxiv · Aug 11, 2021 · PreprintImmunology

Evaluation of mRNA-1273 against SARS-CoV-2 B.1.351 Infection in Nonhuman Primates

K. S. Corbett, A. Werner, S. O'Connell, M. Gagne, L. Lai, J. Moliva, B. Flynn, A. Choi, M. Koch, K. E. Foulds, S. Andrew, D. Flebbe, E. Lamb, S. T. Nurmukhambetova, S. Provost, , M. Suthar

This study evaluates mRNA-1273 vaccine efficacy against SARS-CoV-2 B.1.351 in nonhuman primates, finding that two doses significantly reduce viral replication in the airways.

bioRxiv · May 21, 2021 · PreprintImmunology

Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates

K. S. Corbett, M. C. Nason, B. Flach, M. Gagne, S. O'Connell, T. S. Johnston, S. N. Shah, V. V. Edara, K. Floyd, L. Lai, C. McDanal, J. R. Francica, B. Flynn, K. Wu, A. Choi, , Leung

This study shows that mRNA-1273 vaccine-induced antibody responses correlate with protection against SARS-CoV-2 infection in nonhuman primates.

bioRxiv · Apr 20, 2021 · PreprintImmunology

mRNA-1273 efficacy in a severe COVID-19 model: attenuated activation of pulmonary immune cells after challenge

M. Meyer, Y. Wang, D. Edwards, G. R. Smith, A. B. Rubenstein, P. Ramanathan, C. E. Mire, C. Pietzsch, X. Chen, Y. Ge, W. S. Cheng, C. Henry, A. Woods, L. Ma, G. B. E. Stewart-Jones, , A. Bukreyev

This study evaluates mRNA-1273 vaccine efficacy in hamsters, showing reduced pulmonary immune activation and improved disease outcomes after prime-boost vaccination.

bioRxiv · Jan 25, 2021 · PreprintImmunology

The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates

D. Li, R. J. Edwards, K. Manne, D. R. Martinez, A. Schafer, S. M. Alam, K. Wiehe, X. Lu, R. Parks, L. L. Sutherland, T. H. Oguin, C. McDanal, L. G. Perez, K. Mansouri, S. M. C. Gobeil, , Petzol

This study examines SARS-CoV-2 neutralizing and infection-enhancing antibodies, showing in vitro enhancement does not always lead to in vivo disease enhancement, but can cause increased lung inflammation in monkeys.

bioRxiv · Dec 31, 2020 · PreprintImmunology

SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness

K. S. Corbett, D. Edwards, S. R. Leist, O. M. Abiona, S. Boyoglu-Barnum, R. A. Gillespie, S. Himansu, A. Schafer, C. T. Ziwawo, A. T. DiPiazza, K. H. Dinnon, S. M. Elbashir, C. A. Shaw, A. Woods, E. J. Fritch, , Wang

This paper describes the development of an mRNA vaccine (mRNA-1273) against SARS-CoV-2, showing it induces neutralizing antibodies and CD8 T cell responses and protects mice from infection.

bioRxiv · Jun 11, 2020Immunology